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Topical Latanoprost Does Not Cause Macular 
Thickening after Uncomplicated Cataract Surgery
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Purpose: To explore changes in central macular thickness (CMT) after a two-month period 
of glaucoma therapy with topical latanoprost after uneventful phacoemulsification.
Methods: Forty-one eyes of 31 patients with primary open angle or pseudoexfoliative 
glaucoma who required glaucoma medications after cataract surgery were prospectively 
enrolled. All eyes had undergone uneventful phacoemulsification with intraocular 
lens implantation at least 4 months before initiation of latanoprost. After a complete 
ophthalmic examination, spectral-domain optical coherence tomography (SD-OCT) and 
fluorescein angiography (FA) were performed at baseline before starting latanoprost. 
All eyes received latanoprost for 2 months, and clinical examinations were repeated 
one and two months afterwards; OCT and FA were repeated after 2 months. Outcome 
measures were CMT and loss of more than 2 lines of best corrected visual acuity (BCVA).
Results: Mean patient age was 71.6±7.8 years. Intraocular pressure decreased from 
21.5±3.4 mmHg to 14.4±2.6 mmHg (p<0.001) at 2 months. None of the eyes developed 
reduction of BCVA exceeding 2 lines, or angiographic cystoid macular edema (CME). 
Likewise no significant change was noted in CMT (249.9±29.8 vs 248.8±30.7µm), 
average macular thickness (274.5±15.0 vs 273.8±17.0µm), or macular volume (9.6±1.0 
vs 9.6±1.1µm2) after treatment as compared to baseline (P>0.05 for all comparisons). 
Conclusion: Topical use of latanoprost later than 4 months after uncomplicated cataract 
surgery does not seem to predispose to increased macular thickness or CME and may 
safely be used in this setting.
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INTRODUCTION
Latanoprost ophthalmic solution 0.005% (Xalatan, 
Pfizer Inc., MY, USA) has become a popular 
agent for the treatment of elevated intraocular 
pressure (IOP) and glaucoma since its approval 
by the U.S. Food and Drug Administration in 
June 1996. Despite the efficacy of latanoprost in 
lowering IOP through an increase in uveoscleral 
outflow as a prostaglandin analogue, certain 
ocular side effects have been associated with 
this drug since early studies. These include 
increased iris pigmentation, mild anterior 
segment inflammation, hypertrichosis, increased 
eyelash pigmentation, iritis, anterior uveitis, 
choroidal effusion and cystoid macular edema 
(CME).1-3
It was after several reports of an association 
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between latanoprost use and CME, and also 
resolution of CME after discontinuation of 
latanoprost, that concerns arose about the use 
of latanoprost especially in patients at high risk 
of CME. Most of these studies however, reported 
CME after cataract surgery either in high risk 
eyes (with torn posterior capsule or aphakia) 
or when there was blood ocular barrier (BOB) 
disruption, i.e. during the early postoperative 
period.4
Optical coherence tomography (OCT) has 
been reported to have high sensitivity and 
specificity for detecting CME as compared 
to fluorescein angiography (FA).5 Yet studies 
evaluating macular thickness with OCT after 
use of latanoprost are sparse.6-12
Postoperative inflammation after cataract 
surgery has been evaluated by several authors 
using laser flare meters which have shown that 
postoperative flare values return to baseline 8-12 
weeks after cataract surgery.13-15
In this prospective interventional case 
series, we studied changes in macular thickness 
and macular volume using spectral-domain 
OCT (SD-OCT) after topical administration of 
latanoprost for a two-month period at least 4 
months after uneventful phacoemulsification 
and intraocular lens (IOL) implantation. We 
initiated latanoprost at least 4 months after 
surgery, trying to avoid the period of BOB 
instability following uncomplicated cataract 
surgery.
METHODS
This prospective interventional case series 
included patients with glaucoma at Farabi 
Eye Hospital from 2007 to 2009. In accordance 
with the Declaration of Helsinki on human 
investigations, informed consent was obtained 
from all patients. Inclusion criteria consisted 
of uncontrolled primary open angle glaucoma 
(POAG) or pseudoexfoliative glaucoma (PXG) 
and uncomplicated cataract surgery with 
intraocular lens (IOL) implantation within 
the capsular bag which was performed by a 
single surgeon (SM) at least 4 months prior to 
initiating latanoprost. Exclusion criteria were 
history of any kind of ocular trauma, diabetic 
or inflammatory eye disease, laser procedures 
and intraocular surgery (including filtering 
surgery). Patients with anterior chamber IOLs 
and systemic steroid use were also excluded. 
Furthermore, patients with cell or flare on slit 
lamp examination, macular thickness >300 
µm and clinical or angiographic CME before 
administration of latanoprost were excluded.
Eventually, 41 eyes of 31 patients fulfilled 
the study criteria and underwent a complete 
ophthalmologic examination including 
determination of best corrected visual acuity 
(BCVA), slit lamp biomicroscopy, indirect 
ophthalmoscopy and IOP measurement using 
a Goldmann applanation tonometer. Corneal 
thickness was measured during the day using 
a pachymeter (Sonomed 200P+Micropach, 
Sonomed Inc., NY, USA). FA was performed 
using a fluorescein angiography system 
(Heidelberg instrument, Heidelberg, Germany) 
and OCT was performed employing Cirrus SD-
OCT (Carl Ziess Meditec Inc., Germany) for all 
patients, and macular thickness and volume 
were recorded.
Xalatan was added to the glaucoma regimen 
or used as the first line of therapy. Patients were 
instructed to use an Amsler grid for checking 
macular function and were asked to report 
any visual changes. After one month, clinical 
examinations were repeated and patients were 
reassessed for drug intolerance, adverse reactions 
and compliance. At the end of the second month, 
the ophthalmic examination was repeated and 
FA and OCT imaging were obtained. On OCT, 
macular edema was defined as cyst formation, 
in addition to increased foveal and macular 
thickness. On FA, incomplete or 360-degree 
perifoveal hyperfluorescence (clover shaped) 
due to leakage was considered as angiographic 
CME. Central macular thickness (CMT), macular 
volume and presence of any cystoid changes 
were recorded. Latanoprost was discontinued in 
case of an increase exceeding 15 µm in CMT, a 
decrease of more than one Snellen line in BCVA, 
or leakage on FA. These cases would be followed 
for a longer period and control OCT would be 
performed over the next months.
Data analysis was performed using the 
SPSS software (Version 16, Chicago, USA). The 
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paired t-test was used to compare CMT, IOP and 
macular volume before and after administration 
of latanoprost. Student t-test was employed to 
compare the variables between POAG and PXF 
subgroups. Significance level was set at P<0.05.
RESULTS
Forty-one eyes of 31 (including 19 male) patients 
with mean age of 71.6±7.8 (range, 55-87) years 
were studied. Twenty-eight eyes had POAG 
and 13 eyes had PXG. Nine eyes were on 
timolol 0.5% concurrently at the time of study. 
Mean uncorrected visual acuity was 20/40 
(range, 20/50-20/20) before administration of 
latanoprost.
No significant change was observed in 
central foveal thickness (Fig. 1), average macular 
thickness, and macular volume after latanoprost 
challenge (P>0.05 for all comparisons, Table 1).
None of the patients experienced a decrease 
of more than 1 Snellen line in BCVA. There was 
no case of clinical or angiographic CME after 
treatment. Mean pachymetry decreased from 539 
to 529 microns (P<0.001, Table 1) and mean IOP 
was decreased from 21.5±3.4 to 14.4±2.6 mmHg 
after using latanoprost (P<0.001).
There were no differences between the 
POAG and PXG subgroups in terms of changes in 
IOP, central macular thickness, average macular 
thickness, macular volume and pachymetry 
(Table 2). 
In one case, central foveal thickness increased 
by 16 µm with no change in BCVA, however 
FA did not show any leakage or abnormality. 
After discontinuation of latanoprost, the patient 
was checked for BCVA and SD-OCT, one and 
three months later which revealed no clinically 
significant change as compared to baseline. 
DISCUSSION 
In the current study, latanoprost was not 
associated with CME, increased macular thickness 
or decreased visual acuity in pseudophakic 
eyes at least 4 months after uncomplicated 
cataract surgery. CME is a common pathway 
in many ocular pathologies resulting in cystic 
accumulation of extracellular intraretinal fluid 
in the outer plexiform and inner nuclear layers 
of the retina due to breakdown in the BOB.8
Since the introduction of latanoprost, 
there have been reports of CME in association 
with its use. Review of the literature implies 
that latanoprost should be used with caution 
in eyes with multiple risk factors for CME. 
Some authors have considered rupture of the 
Before After P-value
IOP†
(mmHg)
21.5±3.4
(15-28)
14.4±2.6
(8-19)
0.000*
Central macular 
thickness (µm)
249.8±29.8
(137-294)
248.8±30.7
(135-295)
0.37*
Average macular 
thickness (µm)
274.5±15.0
(227-300)
273.8±17.0
(219-312)
0.51*
Macular volume 
(mm3)
9.6±1.0
(5.5-11.0)
9.6±1.1
(5.20-11.3)
0.48*
Pachymetry
(µm)
539.8±40.8
(470-623)
529.9±35.5
(470-610)
0.000*
Table 1. Variables before and after latanoprost therapy
* Paired t-test
† Intraocular pressure
POAG PXG P-value
Number 28 13
IOP† (mmHg) -7.2±3.8 -7.00±2.9 0.85*
Central macular
thickness (µm)
0.2±5.9 -3.7±9.9 0.20*
Macular volume (mm3) -0.1±0.3 0.10±0.3 0.07*
Average macular
thickness (µm)
0.7±1.1 0.6±1.2 0.84*
Pachymetry (µm) -10.5±13.3 -8.1±10.8 0.68*
Table 2. Changes in study variables from baseline 
in eyes with open angle glaucoma (POAG) and 
pseudoexfoliation glaucoma (PXG)
*Student t-test
† Intraocular pressure
Figure 1. Central macular thickness before and after 
administration of latanoprost.
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posterior capsule as a relative contraindication 
for latanoprost use.7 However, a definite 
conclusion cannot be made about the causal 
relation between latanoprost use and CME based 
on the existing evidence. Eyes afflicted with 
CME following latanoprost administration in 
the literature, had many concurrent risk factors 
for CME.7,8 Preservatives in many antiglaucoma 
eye drops have been shown to increase synthesis 
of prostaglandins and other substances which 
intensify postoperative inflammation, and the 
term pseudophakic preservative maculopathy 
has been proposed for CME caused by eye drops 
such as timolol and latanoprost.16 Moreover, 
pharmacologic studies have demonstrated 
that latanoprost is not vasoactive even at 
concentrations well above therapeutic levels.9 
Well-designed controlled clinical trials are 
needed to elucidate the association between 
latanoprost and macular changes while 
excluding other possible causes of CME. 
In a study on patients with uncomplicated 
phacoemulsification cataract surgery, Honyng 
et al,10 treated 24 cases unilaterally for 4 weeks 
and reported no evidence of macular edema 
(based on FA) or decreased visual acuity. In a 
retrospective study on 162 pseudophakic eyes 
after excluding eyes with apparent CME risk 
factors, 4 cases of CME were detected after 
uncomplicated cataract surgery associated 
with latanoprost usage. However, all these 4 
cases were taking latanoprost before surgery 
without discontinuation of the agent. Moreover, 
CME was diagnosed only based on slit lamp 
biomicroscopy.11 
Besides the studies mentioned above,10,11 
there are few case reports describing CME 
after uncomplicated cataract surgery. In a 
case report, two pseudophakic eyes receiving 
latanoprost developed symptomatic CME 
with blurred vision in the first postoperative 
month. After discontinuation of latanoprost and 
initiation of non-steroidal anti-inflammatory eye 
drops together with oral acetazolamide, their 
symptoms abated and CME disappeared. The 
authors recommended use of latanoprost with 
caution in pseudophakic patients.12
To the best of our knowledge, this is the first 
study addressing administration of latanoprost 
in low risk pseudophakic glaucomatous patients 
utilizing SD-OCT for evaluating the macula. As 
mentioned above, we excluded patients with 
high risk characteristics for CME. Postoperatively 
we followed the patients for at least 4 months, 
trying to avoid the period of BOB instability due 
to uncomplicated cataract surgery. In most of 
the previous studies, CME occurred following 
uncomplicated surgery while the patients had 
been using latanoprost perioperatively, i.e. when 
the BOB is unstable. 
We used a newer version of OCT (Cirrus 
SD-OCT, Carl Zeiss Company) to evaluate 
central macular thickness, average macular 
thickness and macular volume. Cirrus SD-
OCT is superior to Stratus OCT for evaluating 
macular thickness.17
FA was the gold standard for diagnosis 
of CME for a long time.18 Research on novel 
methods of assessing CME yielded newer 
findings. Antellif et al5 reported 96% sensitivity 
and 100% specificity for OCT (OCT 2000 scanner, 
Humphrey Instruments, San Leandro, CA, USA) 
in detecting CME. Moreover, it has been shown 
that SD-OCT demonstrates greater sensitivity 
than FA in detecting CME, particularly in 
cases associated with retinal vein occlusion, 
diabetic retinopathy and age-related macular 
degeneration.19 Another study reported that 
OCT is as effective as FA in detecting CME but is 
superior in demonstrating the axial distribution 
of fluid.5 It was with respect to these studies that 
OCT gradually became the standard method for 
diagnosis of CME.
Macular thickness is a strong and 
independent predictor of macular edema.20,21 
Nussenblatt et al22 reported that the degree of 
macular thickening rather than the presence 
of macular edema, is significantly correlated 
with visual acuity. Chan et al23 demonstrated 
excellent interobserver, intraobserver and 
intervisit reproducibility for OCT in detecting 
macular thickness. Average reproducibility for 
central foveal thickness was 11 µm in healthy 
patients and approximately 20 µm in diabetic 
patients. Newer OCTs have been reported to 
have even less variation in measuring central 
foveal thickness.24 We considered any change 
exceeding 15 µm in macular thickness as 
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significant, discontinued latanoprost in such 
cases and followed the patients more carefully. 
The same level of change in macular thickness 
was selected by Sourdille et al25 for evaluation 
of CME after cataract surgery. Our sample size 
with type 1 error of 0.05 had 87% power to 
detect a 15 µm change in macular thickness 
assuming a standard deviation of 20 and 35 µm 
before and after administration of latanoprost, 
respectively. 
In our study, we observed no decrease 
in BCVA, or change in macular thickness or 
macular volume; these findings demonstrate 
that there may be no change in BOB integrity 
due to latanoprost use following uncomplicated 
cataract surgery. This is the first time macular 
volume is used as a criterion for evaluation of 
BOB. Macular volume may be a useful parameter 
in assessing BOB, however its sensitivity and 
specificity need to be determined in future 
studies.
Postoperative inflammation and the risk 
of CME might be higher in PXG.26 We did not 
detect any difference between POAG and PXG 
groups in terms of changes in macular thickness 
or volume, however the number of cases in the 
PXG subgroup was low in our study. 
IOP decreased significantly (mean reduction 
of 24%) after treatment with latanoprost 
which is consistent with other reports.27 We 
also observed a reduction in central corneal 
thickness of about 10 µm in POAG and about 
8 µm in PXG subgroups in accordance with 
other studies.28,29
Although our sample size was adequate to 
reveal a significant change in macular thickness 
detectable by current imaging technology, this 
study was not powered to detect the potentially 
small risk of angiographic or clinically significant 
CME. Another limitation was the fairly short 
follow-up period. Moreover, our results might 
not be generalized to other prostaglandins such 
as travoprost and bimatoprost. 
In summary this study did not find any 
change in macular thickness and volume after 
administration of latanoprost at least 4 months 
after uncomplicated cataract surgery; therefore 
this medication seems to be safe for lowering 
IOP in these patients.
Conflicts of Interest
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